: Foghorn Therapeutics stock slides 17% premarket on news of partial hold on cancer trial

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Generated by Feedzy